These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26691493)

  • 1. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
    van den Bergh RC; van Casteren NJ; van den Broeck T; Fordyce ER; Gietzmann WK; Stewart F; MacLennan S; Dabestani S; Bellmunt J; Bolla M; Briers E; Cornford P; Joniau S; Mason MD; Matveev V; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Lam TB; Mottet N
    Eur Urol; 2016 May; 69(5):802-20. PubMed ID: 26691493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
    Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.
    Kishan AU; Tendulkar RD; Tran PT; Parker CC; Nguyen PL; Stephenson AJ; Carrie C
    Eur Urol Oncol; 2018 May; 1(1):3-18. PubMed ID: 31100226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
    Mydin AR; Dunne MT; Finn MA; Armstrong JG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
    Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
    Artibani W; Porcaro AB; De Marco V; Cerruto MA; Siracusano S
    Urol Int; 2018; 100(3):251-262. PubMed ID: 29161715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Spratt DE; Dess RT; Zumsteg ZS; Lin DW; Tran PT; Morgan TM; Antonarakis ES; Nguyen PL; Ryan CJ; Sandler HM; Cooperberg MR; Posadas E; Feng FY
    Eur Urol; 2018 Feb; 73(2):156-165. PubMed ID: 28716370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
    Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
    Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; der Kwast THV; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; der Poel HGV; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Mottet N
    Eur Urol; 2021 Feb; 79(2):263-282. PubMed ID: 33039206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.
    Konaka H; Egawa S; Saito S; Yorozu A; Takahashi H; Miyakoda K; Fukushima M; Dokiya T; Yamanaka H; Stone NN; Namiki M
    BMC Cancer; 2012 Mar; 12():110. PubMed ID: 22439742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Comprehensive Cancer Network guidelines for the management of prostate cancer.
    Scherr D; Swindle PW; Scardino PT;
    Urology; 2003 Feb; 61(2 Suppl 1):14-24. PubMed ID: 12667883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.